This multi-center, open-label, single-arm, Phase IIIb study will evaluate the safety and efficacy of RoActemra/Actemra alone or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis patients with an inadequate response to non-biologic DMARDs
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01987479?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
